Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Pfizer, FDA and Hympavzi
Pfizer doubles down with its 2nd FDA hemophilia approval in 6 months
Six months after scoring FDA approval for hemophilia B gene therapy Beqvez, Pf | For the second time in six months, the FDA approved a Pfizer treatment for hemophilia. On Friday the U.S. regulator signed off on Hympavzi,
Pfizer’s Hympavzi Approved for Treatment of Certain Types of Hemophilia
The FDA approved Pfizer’s Hympavzi, which can be an alternative to intravenous infusions often administered multiple times a week.
Pfizer’s Hympavzi Wins FDA Approval to Treat Hemophilia
Pfizer Inc.’s Hympavzi won US approval to treat hemophilia, a potentially deadly genetic disorder that prevents blood from clotting properly.
US FDA approves Pfizer's drug for rare bleeding disorder
The U.S. Food and Drug Administration approved Pfizer's once-a-week injection for the two main types of a rare bleeding disorder called hemophilia, the company said on Friday. The drug, Hympavzi, is given under the skin through an auto-injector pen to prevent or reduce bleeding episodes in hemophilia A or B patients aged 12 years and older.
Pfizer gets FDA approval for Hympavzi for hemophilia
Pfizer (NYSE:PFE) said the FDA has approved its drug Hympavzi for the treatment of certain types of hemophilia. The agency approved Hympavzi as a routine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients aged 12 years and older with hemophilia A without factor VIII inhibitors or hemophilia B without factor IX
3d
Former Pfizer CEO, CFO say they will not be involved in Starboard's campaign against drugmaker
Former Pfizer CEO Ian Read and ex-CFO Frank D'Amelio said they will not be involved with activist investor Starboard Value, ...
4d
What's Happening With Pfizer Stock?
Looking at a slightly longer term, the performance of PFE stock with respect to the index has been quite volatile in recent ...
10d
Is Pfizer a Buy Right Now or a Value Trap?
On top of this, Pfizer also faces key patent expirations of certain older products, and earlier estimated this will result in ...
3d
on MSN
Pfizer’s stock dips after two former execs say they won’t support Starboard
Activist investor Starboard Value claims the pharma giant’s former CEO and CFO were “threatened” into backing current ...
6d
on MSN
Pfizer Stock Rises After It Gets an Activist. What Starboard’s Track Record With Pharma Tells Us.
Starboard has approached two former Pfizer executives, Ian Read and Frank D’Amelio, to assist in its efforts, and they have ...
BioSpace
5d
Activist Investor Starboard Carves $1B Stake in Pfizer, Enlists Former CEO for Help
Pfizer in recent months has implemented aggressive cost-cutting measures to help it weather the steep decline in sales of its ...
6d
Activist investor Starboard Value takes $1 bln stake in Pfizer, sources say
Activist investor Starboard Value has taken a stake of about $1 billion in Pfizer and wants the U.S. drug giant to make ...
MM&M
6d
Activist investor takes $1B stake in Pfizer, aims to turn around company
Citing people familiar with the matter, The Journal reported that Starboard approached former Pfizer CEO Ian Read and CFO ...
1d
3 Reliable Dividend Stocks With Yields Above 5% That You Can Buy With Less Than $100 Right Now
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
Business Wire
3d
Pfizer Declares Fourth-Quarter 2024 Dividend
Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.42 fourth-quarter 2024 dividend on the ...
2d
on MSN
The Score: Tesla, Alphabet, JPMorgan Chase and More Stocks That Defined the Week
Here are some of the major companies whose stocks moved on the week’s news.
3d
Pfizer's cancer drug combo improves overall survival in late-stage study
Pfizer said on Thursday a combination of its drugs, Talzenna and Xtandi, helped prolong the lives of patients with a type of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback